Wells Fargo & Company Lipocine Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.3 - $0.58 $2 - $5	9 Added 1.49%	612 $0
Q4 2022 Feb 13, 2023	BUY	$0.37 - $8.65 $5 - $129	15 Added 2.55%	603 $0
Q3 2022 Nov 14, 2022	SELL	$0.49 - $7.65 $1,471 - $22,980	-3,004 Reduced 83.63%	588 $0
Q2 2022 Aug 12, 2022	BUY	$0.73 - $1.34 $35 - $65	49 Added 1.38%	3,592 $2,000
Q1 2022 May 16, 2022	SELL	$0.89 - $1.85 $506 - $1,052	-569 Reduced 13.84%	3,543 $5,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.2 $0 - $1	1 Added 0.02%	4,112 $5,000
Q3 2021 Nov 15, 2021	BUY	$1.08 - $1.49 $3,210 - $4,429	2,973 Added 261.25%	4,111 $5,000
Q2 2021 Aug 16, 2021	BUY	$1.17 - $1.59 $9 - $12	8 Added 0.71%	1,138 $2,000
Q1 2021 May 13, 2021	BUY	$1.38 - $2.28 $968 - $1,600	702 Added 164.02%	1,130 $2,000
Q4 2020 Feb 09, 2021	BUY	$1.2 - $1.69 $31 - $43	26 Added 6.47%	428 $1,000
Q3 2020 Nov 05, 2020	BUY	$1.21 - $2.23 $229 - $423	190 Added 89.62%	402 $1,000
Q2 2020 Aug 13, 2020	BUY	$0.42 - $1.26 $0 - $1	1 Added 0.47%	212 $0
Q1 2020 May 14, 2020	BUY	$0.32 - $0.77 $67 - $162	211 New	211 $0

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.